May 28, 2025 09:52 AM EDTUpdated 04:45 PM
Financing
Deals
Editor's note

Post-Hoc Live: Is biotech sen­ti­ment re­al­ly as bad as it seems? 

Drew Armstrong

Executive Editor

To­day on Post-Hoc Live, we took a deep dive in­to Found­ing Ed­i­tor John Car­roll’s End­points 100 sur­vey. Twice a year for al­most …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Large phar­ma com­pa­nies spell out rea­sons why tar­iffs will harm US in­vest­ments 

Supreme Court to keep mulling state PBM dis­pute as US urges jus­tices to de­cline case

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

In­tel­lia re­ports case of liv­er tox­i­c­i­ty in AT­TR gene edit­ing study

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times